Active not recruiting
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
I5B-MC-JGDQ - ClinicalTrials.gov - NCT03126591
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Active not recruiting
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
I5B-MC-JGDQ - ClinicalTrials.gov - NCT03126591
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology
Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)
Participant must have an anticipated life expectancy of 3 months or more
Participants must NOT
Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years
Participant must not have received a live-virus vaccine within 30 days of planned treatment
Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years
Trial Summary
Conditions the trial is for
Soft Tissue Sarcoma
What the trial is testing?
Olaratumab, Pembrolizumab
Could I receive a Placebo?
no
Enrollment Goal
37
Trial Dates
July 2017 - March 2021
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology
Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)
Participant must have an anticipated life expectancy of 3 months or more
Participants must NOT
Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years
Participant must not have received a live-virus vaccine within 30 days of planned treatment
Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years
Trial Summary
Conditions the trial is for
Soft Tissue Sarcoma
What the trial is testing?
Olaratumab, Pembrolizumab
Could I receive a Placebo?
no
Enrollment Goal
37
Trial Dates
July 2017 - March 2021
Trial Phase
1
Not the right fit? Sign up to receive updates on new Soft Tissue Sarcoma trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Soft Tissue Sarcoma Resources
